HERANBA Stock Overview
Heranba Industries Limited manufactures, markets, and sells a range of agrochemicals in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Heranba Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹323.55 |
| 52 Week High | ₹426.00 |
| 52 Week Low | ₹282.55 |
| Beta | -0.038 |
| 1 Month Change | 6.24% |
| 3 Month Change | -14.42% |
| 1 Year Change | -12.07% |
| 3 Year Change | -52.61% |
| 5 Year Change | n/a |
| Change since IPO | -60.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| HERANBA | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -0.1% | -2.0% | -1.6% |
| 1Y | -12.1% | 16.5% | 45.0% |
Return vs Industry: HERANBA underperformed the Indian Chemicals industry which returned 16.5% over the past year.
Return vs Market: HERANBA underperformed the Indian Market which returned 45% over the past year.
Price Volatility
| HERANBA volatility | |
|---|---|
| HERANBA Average Weekly Movement | 4.9% |
| Chemicals Industry Average Movement | 6.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: HERANBA has not had significant price volatility in the past 3 months.
Volatility Over Time: HERANBA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 950 | Raghuram Shetty | www.heranba.co.in |
Heranba Industries Limited manufactures, markets, and sells a range of agrochemicals in India. The company provides intermediates, such as cypermethric acid chloride, high CIS CMA and CMAC, high trans CMA and CMAC, bromobenzenes, metaphenoxy benzaldehyde and benzyl alcohol, and NPBR; and technical products, including cypermethrin, deltamethrin, alpha cypermethrin, acephate, lambda cyhalothrin, bifenthrin, and tranfluthrin, as well as tricyclazole, hexaconazole, tebuconazole, glyphosate, metribuzin, clodinafop, and bispyribac sodium. It offers formulations comprising emulsifiable concentrate, water dispersible granule, suspension concentrate, capsule suspension, oil dispersion, concentrated aqueous emulsions, suspoemulsion, and zc formulation.
Heranba Industries Limited Fundamentals Summary
| HERANBA fundamental statistics | |
|---|---|
| Market cap | ₹12.91b |
| Earnings (TTM) | ₹463.60m |
| Revenue (TTM) | ₹12.59b |
27.9x
P/E Ratio1.0x
P/S RatioIs HERANBA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HERANBA income statement (TTM) | |
|---|---|
| Revenue | ₹12.59b |
| Cost of Revenue | ₹8.85b |
| Gross Profit | ₹3.74b |
| Other Expenses | ₹3.28b |
| Earnings | ₹463.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.59 |
| Gross Margin | 29.71% |
| Net Profit Margin | 3.68% |
| Debt/Equity Ratio | 10.7% |
How did HERANBA perform over the long term?
See historical performance and comparison